tradingkey.logo

Immunic Announces Vidofludimus Calcium Reduced Risk Of Disability Worsening By 30% In Primary Progressive Multiple Sclerosis Patients From Phase 2 Calliper Trial

ReutersApr 30, 2025 12:45 PM

- Immunic Inc IMUX.O:

  • IMMUNIC ANNOUNCES VIDOFLUDIMUS CALCIUM REDUCED RISK OF DISABILITY WORSENING BY 30% IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS PATIENTS FROM PHASE 2 CALLIPER TRIAL

  • IMMUNIC INC - 20% REDUCTION IN DISABILITY WORSENING EVENTS IN STUDY POPULATION

  • IMMUNIC INC - FAVORABLE SAFETY PROFILE CONFIRMED, NO NEW SAFETY SIGNALS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI